How Much Does Chemotherapy Cost in 2026?

Chemotherapy cost is unlike almost any other line item in American medicine because the drug itself, not the facility fee or the physician's time, drives nearly all of the bill. A single cycle can run $600 for an older generic cytotoxic agent or $20,000 or more for a modern immunotherapy infusion, and most patients receive multiple cycles spaced two to four weeks apart over three to eight months. The National Cancer Institute and KFF have both documented total course costs ranging from $10,000 to over $200,000 depending on cancer type, drug regimen, and treatment setting. Uninsured patients should check whether they qualify for Medicaid, which covers chemotherapy with minimal or no cost-sharing in every state.

Medicare and most commercial insurers pay for the chemotherapy drug itself using a formula tied to the Average Sales Price (ASP), not a flat fee schedule like most other procedures on this site. This means the drug charge on a chemotherapy bill moves with the manufacturer's national sales data, while the administration service, the nursing time, the chair, and the monitoring, is billed separately and priced far more like a standard office visit. Understanding this split between drug cost and administration cost is the key to reading a chemotherapy bill correctly and catching errors.

This guide covers what chemotherapy costs without insurance in 2026 by drug regimen and site of service, what Medicare Part B and Part D each pay, how to request a Good Faith Estimate before your first infusion under the No Surprises Act, and the self-pay and financial assistance programs, including manufacturer patient assistance programs and nonprofit copay funds, that can substantially lower the bill. The federal No Surprises Act consumer guidance is documented at cms.gov/nosurprises, and the Medicare drug payment methodology is explained at cms.gov.

Chemotherapy Cost by Site of Service in 2026

The biggest cost driver of Chemotherapy is the site of service: where the procedure is performed. 2026 CMS price transparency data confirms a 2-3x billing differential between independent centers and hospital outpatient departments.

Why the Same Procedure Is So Much More at a Hospital

The 2026 chemotherapy cost gap between a hospital outpatient infusion center and an independent oncology practice is driven by the facility component, not the drug. Hospitals bill a separate facility fee on top of the identical drug charge, and that facility fee under the 2026 Hospital Outpatient PPS runs roughly double the professional administration fee paid at a physician office. The chemotherapy drug itself, whether infused at a hospital or an independent practice, is reimbursed under the same Average Sales Price plus 6 percent (ASP+6%) formula, so the drug charge should not differ by site, only the administration and facility charges should.

Independent and community oncology practices have consolidated since 2015, and many now bill under a hospital outpatient provider number even off the main campus, a practice known as provider-based billing. Ask directly whether your infusion suite bills as hospital outpatient or independent physician office; the answer changes your facility fee and, on many commercial plans, your deductible and coinsurance exposure. Some hospitals also qualify for the federal 340B Drug Pricing Program, which discounts their drug acquisition cost, though the discount does not always pass through to the patient.

The practical takeaway for 2026: if your oncologist has privileges at both a hospital-owned infusion center and a freestanding or independent practice, ask which site is billed as non-hospital. Patients routinely save $1,000 to $3,000 per cycle in facility fees alone by choosing an independent oncology practice over a hospital-owned infusion center for the identical drug and dose.

Chemotherapy Cost by Drug Regimen Type in 2026

The infusion chair, the nursing time, and the administration fee are nearly identical no matter what drug is hanging on the pole. What changes the bill by tens of thousands of dollars is the drug class itself. Generic cytotoxic chemotherapy agents, many off-patent for decades, cost a fraction of newer targeted therapies and immunotherapies, which are billed under Medicare Part B if infused, or Part D if taken as a pill at home.

What Medicare Pays for Chemotherapy

Original Medicare Part B covers chemotherapy administered by infusion or injection in a physician office or hospital outpatient department as a Part B drug, using the Average Sales Price plus 6 percent (ASP+6%) reimbursement formula set by CMS. Under the 2026 rates, the professional administration fee runs approximately $187 in a non-facility office setting and the hospital outpatient facility administration fee runs approximately $412, on top of the drug charge itself, which is billed separately and varies by regimen. Beneficiaries pay the standard 20 percent coinsurance after meeting the 2026 Part B deductible of $283, and because chemotherapy drug charges can reach tens of thousands of dollars per cycle, that 20 percent coinsurance has no annual cap under Original Medicare alone.

This uncapped 20 percent exposure is why a Medigap policy matters so much for cancer patients: Medigap plans pay the Part B coinsurance in full, converting a potential $2,000 to $4,000 out-of-pocket bill per infusion cycle into $0. Medicare Advantage enrollees instead have an annual out-of-pocket maximum, capped at $9,350 for in-network care in 2026, but often face prior authorization before starting an expensive biologic or immunotherapy regimen. Original Medicare plus Medigap has no prior authorization requirement for chemotherapy drugs covered under Part B.

Oral chemotherapy pills, taken at home rather than infused, are billed under Medicare Part D instead of Part B, which uses an entirely different structure: a deductible, a defined standard benefit, and a hard annual out-of-pocket cap of $2,100 in 2026 under the Inflation Reduction Act, signed August 16, 2022. Once a Part D enrollee spends $2,100 out of pocket on covered drugs in 2026, including oral chemotherapy, all further covered drug costs for the rest of the calendar year are $0. This cap does not exist for Part B infused chemotherapy without a Medigap policy, making the coverage choice between an infused regimen and an oral regimen financially significant even when both are clinically appropriate.

Under the No Surprises Act, effective January 1, 2022, any patient paying cash or who is uninsured has the right to a written Good Faith Estimate from the oncology practice or hospital before treatment begins. For chemotherapy scheduled at least 10 business days out, the provider must furnish the Good Faith Estimate at least 3 business days before the first infusion. For appointments scheduled 3 to 9 business days out, the Good Faith Estimate must arrive at least 1 business day before service. Because chemotherapy involves multiple recurring cycles, ask the oncology practice for a Good Faith Estimate covering the full planned course, not just the first infusion. The federal portal at cms.gov/nosurprises has complete consumer guidance.

To request a Good Faith Estimate for chemotherapy in 2026: call the oncology practice or infusion center and identify yourself as self-pay or uninsured; ask for a written Good Faith Estimate itemizing the drug HCPCS codes, administration service, and supportive medications planned for the visit; ask whether the estimate covers one cycle or the full treatment plan, since costs compound quickly; confirm the timing (3 business days before service if scheduled 10 or more business days out, 1 business day if scheduled 3 to 9 days out); and keep the estimate for every cycle, you have the right to dispute a final bill that exceeds it by $400 or more within 120 days through the federal dispute resolution portal.

A Good Faith Estimate for chemotherapy is not a guaranteed final bill, and chemotherapy is more prone to cost drift than almost any other procedure on this site because dosing and drug selection can change between cycles based on how the patient responds. Common reasons the actual charges exceed the estimate include: a dose escalation or drug switch based on scan results, an added supportive medication such as a growth factor injection, an unplanned additional cycle, drug wastage from a partially used single-dose vial, and extended monitoring time for an infusion reaction. If the final bill exceeds the Good Faith Estimate by $400 or more, the patient has 120 days from the bill date to file a patient-provider dispute resolution claim at cms.gov/nosurprises.

What Factors Affect Cost

• Drug regimen and class, generic cytotoxic agents versus targeted biologics versus immunotherapy, the single biggest driver of chemotherapy cost by far.
• Site of service (hospital outpatient department versus independent oncology practice), the facility administration fee roughly doubles at a hospital under 2026 Medicare rates.
• Number of cycles and total course duration, most regimens run 4 to 12 cycles spaced 2 to 4 weeks apart over 3 to 8 months.
• Insurance type (Medicare Part B for infused drugs, Medicare Part D for oral pills, ACA-compliant marketplace plan medical benefit, or employer commercial plan), each uses a different cost-sharing structure.
• Manufacturer patient assistance programs (PAPs) and nonprofit copay foundations (Patient Advocate Foundation, HealthWell Foundation, CancerCare, Patient Access Network Foundation), which can cover the drug cost, coinsurance, or deductible for specific cancer diagnoses.
• Hospital chargemaster discount and 501(r) financial assistance policy, nonprofit hospitals must offer income-based charity care, typically starting at 200 to 400 percent of the Federal Poverty Level.
• Medicaid treatment eligibility under the federal Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA) for women diagnosed through a CDC National Breast and Cervical Cancer Early Detection Program (NBCCEDP) screening, regardless of standard state income limits.
• Prior authorization requirements for high-cost biologics and immunotherapy on Medicare Advantage and commercial plans, which can delay treatment and change the covered dose or agent.

Common Chemotherapy Billing Errors

Chemotherapy billing is unusually error-prone because a single infusion visit generates multiple separate charges, the drug, the administration service, supportive medications, and sometimes lab work, each with its own code and payment rule. Check for these errors before paying:

• Leftover single-dose vial amounts (drug wastage) billed to you at full retail price instead of reported separately, ask whether the practice follows the payer's wastage billing policy.
• The chemotherapy drug and the administration service both billed at the full hospital outpatient facility rate when the infusion actually happened at an affiliated but separate independent practice location.
• Supportive anti-nausea or growth-factor injection drugs billed without prior disclosure, always ask for an itemized list of every drug planned for the visit before treatment starts.
• An off-label or non-covered chemotherapy drug administered without an Advance Beneficiary Notice (ABN) under Medicare, if you were not warned in writing that Medicare might deny the claim, you may be able to dispute the bill.
• Home infusion pharmacy dispensing fees billed in addition to, rather than instead of, the standard Part B drug administration charge for the same cycle.
• Duplicate lab or pathology charges billed on the same date as the infusion when the labs were already billed as part of a separate office visit earlier that week.

Frequently Asked Questions